Supernus Pharmaceuticals Inc (FRA:S49)
€ 34.6 0.6 (1.76%) Market Cap: 1.97 Bil Enterprise Value: 1.62 Bil PE Ratio: 34.78 PB Ratio: 2.04 GF Score: 80/100

Supernus Pharmaceuticals Inc at Morgan Stanley Global Healthcare Conference (Virtual) Transcript

Sep 15, 2021 / 03:45PM GMT
Release Date Price: €22.8 (+0.88%)
Rahul Sood;Morgan Stanley;Jack A. Khattar
Research Division,;Supernus Pharmaceuticals, Inc. - Founder, President, CEO, Secretary & Director

Good morning, everyone. This is Rahul Sood here from Morgan Stanley's Healthcare Investment Banking Group. We are joined today by Jack Khattar, President and CEO of Supernus Pharmaceuticals for this fireside chat.

Before we turn -- before I -- we turn it over to Jack, I have some important disclosures to read. For important disclosures, please see the Morgan Stanley research disclosure website at www.morganstanley.com/researchdisclosures. If you have any questions, please reach out to your Morgan Stanley sales representative.

The second housekeeping item is for the audience. If you have any questions for Jack, please use the Q&A portal to type in your questions. I'll be sure to you to ask Jack some of those questions.

With Jack -- with that, Jack, welcome and thanks for joining us today.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot